Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou AGS Medtech CoSHSE:688581 -6.19%89 EV-to-FCF is 16.71 as of Jul. 17, 2026, which is 6% below its 10-year median of 17.72. GuruFocus rates SHSE:688581 with a GF Score™ of 89/100 and a GF Value™ of ¥75.63 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 413 Medical Devices & Instruments companies, Hangzhou AGS Medtech Co ranks better than 62.95% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hangzhou AGS Medtech Co's Enterprise Value is ¥2,214.6 Mil.
Hangzhou AGS Medtech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥132.5 Mil. Therefore, Hangzhou AGS Medtech Co's EV-to-FCF for today is 16.71.
The historical rank and industry rank for Hangzhou AGS Medtech Co's EV-to-FCF or its related term are showing as below:
SHSE:688581'
s EV-to-FCF Range Over the Past 10 Years
Min: 8.29 Med: 17.72 Max: 59.82
Current: 16.71
During the past 9 years, the highest EV-to-FCF of Hangzhou AGS Medtech Co was 59.82. The lowest was 8.29. And the median was 17.72.
SHSE:688581's EV-to-FCF is ranked better than 62.95% of 413
companies
in the Medical Devices & Instruments industry
Industry Median: 23.72
vs SHSE:688581: 16.71
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hangzhou AGS Medtech Co (SHSE:688581) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hangzhou AGS Medtech Co's PE Ratio (TTM) for today is calculated as:
Hangzhou AGS Medtech Co's share price for today is ¥52.25.
Hangzhou AGS Medtech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688581 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Hangzhou AGS Medtech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou AGS Medtech Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou AGS Medtech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hangzhou AGS Medtech Co's EV-to-FCF falls into.
Hangzhou AGS Medtech Co's current Enterprise Value is ¥2,214.6 Mil.
Hangzhou AGS Medtech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥132.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou AGS Medtech Co (SHSE:688581) has a EV-to-FCF of 16.71 as of Jul. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hangzhou AGS Medtech Co and its competitors. This is near median its historical median of 17.72. Over the past decade, Hangzhou AGS Medtech Co's EV-to-FCF has ranged from 8.29 to 59.82. According to the industry distribution chart, Hangzhou AGS Medtech Co ranks #153 out of 413 companies in the Medical Devices & Instruments industry, placing it in the top 37%.
Is Hangzhou AGS Medtech Co's EV-to-FCF too high?
Hangzhou AGS Medtech Co's current EV-to-FCF of 16.71 is near median its 10-year median of 17.72. Over the past 10 years, this metric has ranged from a low of 8.29 to a high of 59.82. The Medical Devices & Instruments industry median EV-to-FCF is 23.72. Hangzhou AGS Medtech Co's value of 16.71 is 29.6% below this industry median. Based on the distribution chart, Hangzhou AGS Medtech Co ranks #153 out of 413 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Hangzhou AGS Medtech Co has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou AGS Medtech Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Hangzhou AGS Medtech Co ranks #153 out of 413 companies for EV-to-FCF. This puts Hangzhou AGS Medtech Co in the upper half of its industry. The industry median EV-to-FCF is 23.72. Hangzhou AGS Medtech Co's value of 16.71 is 29.6% below this benchmark. Historically, Hangzhou AGS Medtech Co's own EV-to-FCF has ranged from 8.29 to 59.82 over the past decade. While the company's 10-year median is 17.72 vs. the industry median of 23.72, Hangzhou AGS Medtech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.72, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou AGS Medtech Co's current EV-to-FCF of 16.71 is 29.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hangzhou AGS Medtech Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou AGS Medtech Co's current EV-to-FCF is 16.71, which is near median its own 10-year median of 17.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou AGS Medtech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou AGS Medtech Co (SHSE:688581) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥75.63, compared to a current price of ¥52.25 — trading 30.9% below its estimated fair value. The current EV-to-FCF is 16.71, which is near median its 10-year median of 17.72 and 29.6% below the Medical Devices & Instruments industry median of 23.72. Hangzhou AGS Medtech Co's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hangzhou AGS Medtech Co (SHSE:688581), the current EV-to-FCF is 16.71 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou AGS Medtech Co (SHSE:688581) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou AGS Medtech Co stock appears to be undervalued.
The current stock price of ¥52.25 is trading 30.9% below its estimated GF Value™ of ¥75.63.
GuruFocus considers Hangzhou AGS Medtech Co to be Significantly Undervalued.
Key valuation signals for SHSE:688581:
EV-to-FCF: 16.71 (near median its 10-year median of 17.72)
GF Value™: ¥75.63 vs. price of ¥52.25 (30.9% below fair value)
Industry Position: 29.6% below the Medical Devices & Instruments median (#153 of 413)
No single metric tells the full story. See the SHSE:688581 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou AGS Medtech Co Ltd is engaged in Research & Development, production, and sales of endoscopic minimally invasive diagnosis and treatment devices. The company upholds the core values of create, insist, share, and provide patients and clinicians with safer and more efficient minimally invasive endoscopic devices, helping patients reduce pain and medical costs.
89GF Score
Get the complete analysis for SHSE:688581
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688581 has been successfully added to your 
